Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Drug resistance and antiretroviral drug development JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY Shafer, R. W., Schapiro, J. M. 2005; 55 (6): 817-820

Abstract

As more drugs for treating HIV have become available, drug resistance profiles within antiretroviral drug classes have become increasingly important for researchers developing new drugs and for clinicians integrating new drugs into their clinical practice. In vitro passage experiments and comprehensive phenotypic susceptibility testing are used for the pre-clinical evaluation of drug resistance. Clinical studies are required, however, to delineate the full spectrum of mutations responsible for resistance to a new drug and to identify the settings in which a new drug is likely to be most useful for salvage therapy.

View details for DOI 10.1093/jac/dki127

View details for Web of Science ID 000230028100002

View details for PubMedID 15845781

View details for PubMedCentralID PMC2547472